{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:54:18Z","timestamp":1792079658814,"version":"4.4.0"},"reference-count":129,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100014786","name":"Northern Border University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014786","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007471","name":"Northern Borders University","doi-asserted-by":"publisher","award":["NBU-CRP-2025-2043"],"award-info":[{"award-number":["NBU-CRP-2025-2043"]}],"id":[{"id":"10.13039\/501100007471","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.cca.2025.120387","type":"journal-article","created":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T17:40:36Z","timestamp":1748194836000},"page":"120387","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["MUC1 as a diagnostic biomarker and siRNA-based therapeutic target in breast cancer: A clinical chemistry perspective"],"prefix":"10.1016","volume":"576","author":[{"given":"Surya Nath","family":"Pandey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Arockia","family":"Babu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haider","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malathi","family":"H","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laxmidhar","family":"Maharana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohit","family":"Rana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd","family":"Imran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2025.120387_b0005","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","article-title":"Current and future burden of breast cancer: Global statistics for 2020 and 2040","volume":"66","author":"Arnold","year":"2022","journal-title":"Breast"},{"issue":"2","key":"10.1016\/j.cca.2025.120387_b0010","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s40120-021-00279-8","article-title":"Hematoma evacuation via image-guided para-corticospinal tract approach in patients with spontaneous intracerebral hemorrhage","volume":"10","author":"Zhang","year":"2021","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.cca.2025.120387_b0015","unstructured":"Supplemental Screening as an Adjunct to Mammography for Breast Cancer Screening in People With Dense Breasts: A Health Technology Assessment. Ont Health Technol Assess Ser, 2023. 23(9) 1\u2013293."},{"key":"10.1016\/j.cca.2025.120387_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.saa.2022.122000","article-title":"Serum Raman spectroscopy combined with convolutional neural network for rapid diagnosis of HER2-positive and triple-negative breast cancer","volume":"286","author":"Zeng","year":"2023","journal-title":"Spectrochim. Acta A Mol. Biomol. Spectrosc."},{"issue":"1","key":"10.1016\/j.cca.2025.120387_b0025","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13058-025-02016-7","article-title":"Identification of minimal residual disease using the clonesight test for ultrasensitive ctDNA detection to anticipate late relapse in early breast cancer","volume":"27","author":"Comino-M\u00e9ndez","year":"2025","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.cca.2025.120387_b0030","doi-asserted-by":"crossref","DOI":"10.3788\/COL202018.051701","article-title":"Detection of breast cancer based on novel porous silicon Bragg reflector surface-enhanced Raman spectroscopy-active structure","volume":"18","author":"Ma","year":"2020","journal-title":"Chin. Opt. Lett."},{"issue":"6","key":"10.1016\/j.cca.2025.120387_b0035","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15061640","article-title":"Mucins as potential biomarkers for early detection of cancer","volume":"15","author":"Gautam","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cca.2025.120387_b0040","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.breast.2020.05.005","article-title":"Clinical utility of tumour marker velocity of cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) in breast cancer surveillance","volume":"52","author":"Hing","year":"2020","journal-title":"Breast"},{"key":"10.1016\/j.cca.2025.120387_b0045","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/4889616","article-title":"Diagnostic value of carcinoembryonic antigen combined with multi-inflammatory cell ratios in colorectal cancer","volume":"2022","author":"Liu","year":"2022","journal-title":"Dis. Markers"},{"issue":"1","key":"10.1016\/j.cca.2025.120387_b0050","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2024.2416604","article-title":"Construction of circRNA-miRNA-mRNA ceRNA regulatory network and screening of diagnostic targets for tuberculosis","volume":"56","author":"Pu","year":"2024","journal-title":"Ann. Med."},{"issue":"24","key":"10.1016\/j.cca.2025.120387_b0055","doi-asserted-by":"crossref","first-page":"18365","DOI":"10.1021\/acscatal.4c05719","article-title":"Comprehensive investigations of MUC1 O-glycosylation process reveal initial site preference by the polypeptide GalNAc transferases","volume":"14","author":"Zhang","year":"2024","journal-title":"ACS Catal."},{"key":"10.1016\/j.cca.2025.120387_b0060","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.biopha.2017.08.120","article-title":"IL-1\u03b2-induced NF-\u03baB activation down-regulates miR-506 expression to promotes osteosarcoma cell growth through JAG1","volume":"95","author":"Hu","year":"2017","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.cca.2025.120387_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.188889","article-title":"The hidden potential of glycomarkers: Glycosylation studies in the service of cancer diagnosis and treatment","volume":"1878","author":"Grzesik","year":"2023","journal-title":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"},{"issue":"3","key":"10.1016\/j.cca.2025.120387_b0070","doi-asserted-by":"crossref","first-page":"366","DOI":"10.37349\/etat.2023.00140","article-title":"Capitalizing glycomic changes for improved biomarker-based cancer diagnostics","volume":"4","author":"Silva","year":"2023","journal-title":"Explor Target Antitumor Ther"},{"key":"10.1016\/j.cca.2025.120387_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113993","article-title":"Disorders of cancer metabolism: The therapeutic potential of cannabinoids","volume":"157","author":"Sun","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.cca.2025.120387_b0080","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13045-024-01532-x","article-title":"Decoding the glycoproteome: a new frontier for biomarker discovery in cancer","volume":"17","author":"He","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.cca.2025.120387_b0085","article-title":"Synergistic effect of VEGF and SDF-1\u03b1 in endothelial progenitor cells and vascular smooth muscle cells","volume":"13","author":"Yang","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.cca.2025.120387_b0090","first-page":"504","article-title":"Targeting MUC1 and JNK by RNA interference and inhibitor inhibit the development of hepatocellular carcinoma","volume":"108","author":"Wang","year":"2017","journal-title":"Can. Sci."},{"issue":"7","key":"10.1016\/j.cca.2025.120387_b0095","doi-asserted-by":"crossref","DOI":"10.3390\/ph16070970","article-title":"Advances with lipid-based nanosystems for siRNA delivery to breast cancers","volume":"16","author":"Subhan","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"6","key":"10.1016\/j.cca.2025.120387_b0100","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.molmed.2014.02.007","article-title":"MUC1: a multifaceted oncoprotein with a key role in cancer progression","volume":"20","author":"Nath","year":"2014","journal-title":"Trends Mol. Med."},{"issue":"5","key":"10.1016\/j.cca.2025.120387_b0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0125994","article-title":"The breast cancer-associated glycoforms of MUC1, MUC1-Tn and sialyl-Tn, are expressed in COSMC wild-type cells and bind the C-type lectin MGL","volume":"10","author":"Beatson","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.cca.2025.120387_b0110","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/bs.acr.2022.09.001","article-title":"Measuring the multifaceted roles of mucin-domain glycoproteins in cancer","volume":"157","author":"Riley","year":"2023","journal-title":"Adv Can. Res"},{"issue":"1","key":"10.1016\/j.cca.2025.120387_b0115","doi-asserted-by":"crossref","first-page":"6651","DOI":"10.1038\/s41598-021-85029-4","article-title":"Combined detection of CA15-3, CEA, and SF in serum and tissue of canine mammary gland tumor patients","volume":"11","author":"Fan","year":"2021","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.cca.2025.120387_b0120","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/labinvest.2017.53","article-title":"Assessment of tumor characteristics based on glycoform analysis of membrane-tethered MUC1","volume":"97","author":"Matsuda","year":"2017","journal-title":"Lab. Invest."},{"key":"10.1016\/j.cca.2025.120387_b0125","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/1471-2407-6-220","article-title":"CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer","volume":"6","author":"Al-azawi","year":"2006","journal-title":"BMC Can."},{"issue":"12","key":"10.1016\/j.cca.2025.120387_b0130","doi-asserted-by":"crossref","first-page":"8340","DOI":"10.1021\/acs.analchem.0c00807","article-title":"Dual-probe approach for mass spectrometric quantification of MUC1-specific terminal Gal\/GalNAc in situ","volume":"92","author":"Sun","year":"2020","journal-title":"Anal. Chem."},{"issue":"3","key":"10.1016\/j.cca.2025.120387_b0135","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/mas.21873","article-title":"Analysis of carbohydrates and glycoconjugates by matrix-assisted laser desorption\/ionization mass spectrometry: an update for 2021-2022","volume":"44","author":"Harvey","year":"2025","journal-title":"Mass Spectrom. Rev."},{"issue":"3","key":"10.1016\/j.cca.2025.120387_b0140","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1128\/CMR.00074-09","article-title":"Validation of laboratory-developed molecular assays for infectious diseases","volume":"23","author":"Burd","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.cca.2025.120387_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.microc.2020.105647","article-title":"Determination of nine mental drugs in human plasma using solid-phase supported liquid-liquid extraction and HPLC-MS\/MS","volume":"160","author":"Zheng","year":"2021","journal-title":"Microchem. J."},{"issue":"7","key":"10.1016\/j.cca.2025.120387_b0150","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1021\/acs.jproteome.0c00050","article-title":"HILIC\u2013MRM\u2013MS for linkage-specific separation of sialylated glycopeptides to quantify prostate-specific antigen proteoforms","volume":"19","author":"van der Burgt","year":"2020","journal-title":"J. Proteome Res."},{"issue":"2","key":"10.1016\/j.cca.2025.120387_b0155","first-page":"627","article-title":"Receiver operating characteristic (ROC) curve analysis for medical diagnostic test evaluation","volume":"4","author":"Hajian-Tilaki","year":"2013","journal-title":"Caspian J. Intern. Med."},{"issue":"1","key":"10.1016\/j.cca.2025.120387_b0160","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3348\/kjr.2004.5.1.11","article-title":"Receiver operating characteristic (ROC) curve: practical review for radiologists","volume":"5","author":"Park","year":"2004","journal-title":"Korean J. Radiol."},{"issue":"23\u201324","key":"10.1016\/j.cca.2025.120387_b0165","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.cca.2010.08.039","article-title":"CA 15-3: uses and limitation as a biomarker for breast cancer","volume":"411","author":"Duffy","year":"2010","journal-title":"Clin. Chim. Acta"},{"issue":"2","key":"10.1016\/j.cca.2025.120387_b0170","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4174\/astr.2016.90.2.57","article-title":"Clinical significance of serum CA15-3 as a prognostic parameter during follow-up periods in patients with breast cancer","volume":"90","author":"Chu","year":"2016","journal-title":"Ann Surg Treat Res"},{"issue":"2","key":"10.1016\/j.cca.2025.120387_b0175","doi-asserted-by":"crossref","first-page":"126","DOI":"10.4048\/jbc.2023.26.e17","article-title":"Prognostic impact of elevation of cancer antigen 15-3 (CA15-3) in patients with early breast cancer with normal serum CA15-3 level","volume":"26","author":"Ryu","year":"2023","journal-title":"J. Breast Can."},{"key":"10.1016\/j.cca.2025.120387_b0180","doi-asserted-by":"crossref","first-page":"57","DOI":"10.33393\/jcb.2022.2446","article-title":"Diagnostic impact of CEA and CA 15-3 on chemotherapy monitoring of breast cancer patients","volume":"11","author":"Hasan","year":"2022","journal-title":"J. Circ. Biomark."},{"issue":"4","key":"10.1016\/j.cca.2025.120387_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100203","article-title":"Detection of secondary metastatic breast cancer by measurement of plasma CA 15.3","volume":"6","author":"De Cock","year":"2021","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.cca.2025.120387_b0190","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3892\/mco.2014.419","article-title":"Association of CA 15-3 and CEA with clinicopathological parameters in patients with metastatic breast cancer","volume":"3","author":"Geng","year":"2015","journal-title":"Mol. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.cca.2025.120387_b0195","doi-asserted-by":"crossref","first-page":"412","DOI":"10.5306\/wjco.v5.i3.412","article-title":"Biological subtypes of breast cancer: prognostic and therapeutic implications","volume":"5","author":"Yersal","year":"2014","journal-title":"World J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.cca.2025.120387_b0200","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","article-title":"Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment","volume":"9","author":"Garrido-Castro","year":"2019","journal-title":"CancerDiscov"},{"issue":"6","key":"10.1016\/j.cca.2025.120387_b0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158259","article-title":"Extensive transcriptomic and genomic analysis provides new insights about luminal breast cancers","volume":"11","author":"Tishchenko","year":"2016","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.cca.2025.120387_b0210","article-title":"Advances in siRNA drug delivery strategies for targeted TNBC therapy","volume":"11","author":"Subhan","year":"2024","journal-title":"Bioengineering (basel)"},{"issue":"11","key":"10.1016\/j.cca.2025.120387_b0215","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1258\/ebm.2012.011326","article-title":"Monitoring the development of xenograft triple-negative breast cancer models using diffusion-weighted magnetic resonance imaging","volume":"237","author":"Stephen","year":"2012","journal-title":"Exp. Biol. Med. (Maywood)"},{"issue":"10","key":"10.1016\/j.cca.2025.120387_b0220","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1007\/s13346-024-01638-2","article-title":"Lipid nanoparticles-based RNA therapies for breast cancer treatment","volume":"14","author":"Serpico","year":"2024","journal-title":"Drug Deliv. Transl. Res."},{"issue":"2","key":"10.1016\/j.cca.2025.120387_b0225","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1101\/gad.862301","article-title":"RNA interference is mediated by 21- and 22-nucleotide RNAs","volume":"15","author":"Elbashir","year":"2001","journal-title":"Genes Dev."},{"issue":"2","key":"10.1016\/j.cca.2025.120387_b0230","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1021\/acsomega.1c06455","article-title":"siRNA seed region is divided into two functionally different domains in RNA interference in response to 2\u2032-OMe modifications","volume":"7","author":"Kobayashi","year":"2022","journal-title":"ACS Omega"},{"issue":"10","key":"10.1016\/j.cca.2025.120387_b0235","doi-asserted-by":"crossref","DOI":"10.3390\/ph13100294","article-title":"Overcoming barriers for siRNA therapeutics: from bench to bedside","volume":"13","author":"Sajid","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.cca.2025.120387_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124545","article-title":"Enhancing siRNA cancer therapy: multifaceted strategies with lipid and polymer-based carrier systems","volume":"663","author":"Dastgerdi","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.cca.2025.120387_b0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.onano.2023.100173","article-title":"Dendrimer-based nanocomposites for the production of RNA delivery systems","volume":"13","author":"Lim","year":"2023","journal-title":"OpenNano"},{"issue":"10","key":"10.1016\/j.cca.2025.120387_b0250","doi-asserted-by":"crossref","DOI":"10.3390\/cells12101416","article-title":"Current strategies for exosome cargo loading and targeting delivery","volume":"12","author":"Zeng","year":"2023","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.cca.2025.120387_b0255","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12929-023-00981-9","article-title":"Small interfering RNA (siRNA)-based therapeutic applications against viruses: principles, potential, and challenges","volume":"30","author":"Kang","year":"2023","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.cca.2025.120387_b0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbi.2021.102014","article-title":"The initiation of RNA interference (RNAi) in plants","volume":"61","author":"Hung","year":"2021","journal-title":"Curr. Opin. Plant Biol."},{"issue":"1","key":"10.1016\/j.cca.2025.120387_b0265","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1186\/s12951-023-02147-z","article-title":"Engineering siRNA therapeutics: challenges and strategies","volume":"21","author":"Ali Zaidi","year":"2023","journal-title":"J Nanobiotechnology"},{"key":"10.1016\/j.cca.2025.120387_b0270","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/B978-0-12-800148-6.00004-3","article-title":"Lipid nanoparticles for short interfering RNA delivery","volume":"88","author":"Leung","year":"2014","journal-title":"Adv. Genet."},{"issue":"2","key":"10.1016\/j.cca.2025.120387_b0275","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ymthe.2024.01.005","article-title":"The landscape of nanoparticle-based siRNA delivery and therapeutic development","volume":"32","author":"Moazzam","year":"2024","journal-title":"Mol. Ther."},{"issue":"13","key":"10.1016\/j.cca.2025.120387_b0280","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1158\/0008-5472.CAN-16-0359","article-title":"OncomiR or tumor suppressor? the duplicity of MicroRNAs in cancer","volume":"76","author":"Svoronos","year":"2016","journal-title":"Can. Res"},{"issue":"1","key":"10.1016\/j.cca.2025.120387_b0285","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1177\/1947601909357933","article-title":"MUCIN 1 oncoprotein expression is suppressed by the miR-125b ONCOMIR","volume":"1","author":"Rajabi","year":"2010","journal-title":"Genes Can."},{"key":"10.1016\/j.cca.2025.120387_b0290","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jss.2018.11.030","article-title":"miR-145-5p suppresses breast cancer progression by inhibiting SOX2","volume":"236","author":"Tang","year":"2019","journal-title":"J. Surg. Res."},{"issue":"19","key":"10.1016\/j.cca.2025.120387_b0295","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20194940","article-title":"The regulatory role of microRNAs in breast cancer","volume":"20","author":"Loh","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.cca.2025.120387_b0300","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ncrna.2024.01.016","article-title":"Inhibition of breast cancer cell growth and migration through siRNA-mediated modulation of circ_0009910\/miR-145-5p\/MUC1 axis","volume":"9","author":"Abtin","year":"2024","journal-title":"Non-coding RNA Res."},{"issue":"4","key":"10.1016\/j.cca.2025.120387_b0305","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s10585-005-0745-1","article-title":"A new model for lymphatic metastasis: development of a variant of the MDA-MB-468 human breast cancer cell line that aggressively metastasizes to lymph nodes","volume":"22","author":"Vantyghem","year":"2005","journal-title":"Clin. Exp. Metastasis"},{"issue":"4","key":"10.1016\/j.cca.2025.120387_b0310","doi-asserted-by":"crossref","first-page":"R37","DOI":"10.1186\/bcr1515","article-title":"MUC1 alters oncogenic events and transcription in human breast cancer cells","volume":"8","author":"Hattrup","year":"2006","journal-title":"Breast Can. Res."},{"key":"10.1016\/j.cca.2025.120387_b0315","doi-asserted-by":"crossref","first-page":"65","DOI":"10.25259\/Cytojournal_107_2024","article-title":"Detection of transmembrane protein 100 in breast cancer: Correlation with malignant progression and chemosensitivity","volume":"21","author":"Liu","year":"2024","journal-title":"Cytojournal"},{"key":"10.1016\/j.cca.2025.120387_b0320","doi-asserted-by":"crossref","DOI":"10.1007\/s40005-025-00731-z","article-title":"Disulfide bond-driven nanoassembly of lipophilic epirubicin prodrugs for breast cancer therapy","author":"Yuan","year":"2025","journal-title":"J. Pharm.Investig."},{"key":"10.1016\/j.cca.2025.120387_b0325","doi-asserted-by":"crossref","unstructured":"J. K\u00fchn, et al., The adaptor protein CIN85 assembles intracellular signaling clusters for B cell activation, Sci. Signal 9(434) (2016) ra66.","DOI":"10.1126\/scisignal.aad6275"},{"issue":"7","key":"10.1016\/j.cca.2025.120387_b0330","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1091\/mbc.e03-09-0683","article-title":"CIN85 associates with multiple effectors controlling intracellular trafficking of epidermal growth factor receptors","volume":"15","author":"Kowanetz","year":"2004","journal-title":"Mol. Biol. Cell"},{"issue":"10","key":"10.1016\/j.cca.2025.120387_b0335","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.18632\/oncotarget.1265","article-title":"Altered glycosylation of MUC1 influences its association with CIN85: the role of this novel complex in cancer cell invasion and migration","volume":"4","author":"Cascio","year":"2013","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.cca.2025.120387_b0340","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41423-023-00990-6","article-title":"Dendritic cell subsets in cancer immunity and tumor antigen sensing","volume":"20","author":"Del Prete","year":"2023","journal-title":"Cell Mol. Immunol."},{"issue":"Pt 3","key":"10.1016\/j.cca.2025.120387_b0345","article-title":"Chrysotoxine regulates ferroptosis and the PI3K\/AKT\/mTOR pathway to prevent cervical cancer","volume":"338","author":"Zhou","year":"2025","journal-title":"J. Ethnopharmacol."},{"issue":"2","key":"10.1016\/j.cca.2025.120387_b0350","first-page":"1630","article-title":"Silencing of suppressor of cytokine signaling 1 enhances the immunological effect of mucin 1-calreticulin-primed 4T1 cell-treated dendritic cells in breast cancer treatment","volume":"15","author":"Qin","year":"2018","journal-title":"Oncol. Lett."},{"issue":"12","key":"10.1016\/j.cca.2025.120387_b0355","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22126567","article-title":"MUC1: structure, function, and clinic application in epithelial cancers","volume":"22","author":"Chen","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cca.2025.120387_b0360","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jconrel.2018.07.042","article-title":"Synergistic inhibition of aggressive breast cancer cell migration and invasion by cytoplasmic delivery of anti-RhoC silencing RNA and presentation of EPPT1 peptide on \u201csmart\u201d particles","volume":"289","author":"Kaushal","year":"2018","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.cca.2025.120387_b0365","doi-asserted-by":"crossref","first-page":"25331","DOI":"10.1038\/s41598-024-76798-9","article-title":"Comprehensive pan-cancer analysis reveals ENC1 as a promising prognostic biomarker for tumor microenvironment and therapeutic responses","volume":"14","author":"Cao","year":"2024","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.cca.2025.120387_b0370","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40824-023-00365-y","article-title":"Advanced cancer targeting using aptamer functionalized nanocarriers for site-specific cargo delivery","volume":"27","author":"Narwade","year":"2023","journal-title":"Biomater. Res."},{"key":"10.1016\/j.cca.2025.120387_b0375","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2024.1383495","article-title":"MUC1 aptamer-tethered H40-TEPA-PEG nanoconjugates for targeted siRNA-delivery and gene silencing in breast cancer cells","volume":"12","author":"Salve","year":"2024","journal-title":"Front Bioeng. Biotechnol."},{"issue":"2","key":"10.1016\/j.cca.2025.120387_b0380","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1245\/s10434-024-16454-8","article-title":"Prognostic value of the baseline systemic immune-inflammation index in HER2-positive metastatic breast cancer: exploratory analysis of two prospective trials","volume":"32","author":"Pang","year":"2025","journal-title":"Ann. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.cca.2025.120387_b0385","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.gendis.2022.03.002","article-title":"Drugging IGF-1R in cancer: New insights and emerging opportunities","volume":"10","author":"Wang","year":"2023","journal-title":"Genes Diseases"},{"issue":"17","key":"10.1016\/j.cca.2025.120387_b0390","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25179302","article-title":"Decoding the role of insulin-like growth factor 1 and its isoforms in breast cancer","volume":"25","author":"Kotsifaki","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.cca.2025.120387_b0395","doi-asserted-by":"crossref","first-page":"21","DOI":"10.29252\/ibj.23.1.21","article-title":"Anti-Mucin1 aptamer-conjugated chitosan nanoparticles for targeted co-delivery of docetaxel and IGF-1R siRNA to SKBR3 metastatic breast cancer cells","volume":"23","author":"Jafari","year":"2019","journal-title":"Iran. Biomed. J."},{"key":"10.1016\/j.cca.2025.120387_b0400","first-page":"575","article-title":"Challenges in detection of serum oncoprotein: relevance to breast cancer diagnostics","volume":"13","author":"Lengfeld","year":"2021","journal-title":"Breast Cancer (dove Med Press)"},{"issue":"1","key":"10.1016\/j.cca.2025.120387_b0405","first-page":"145","article-title":"Use of CA15\u20113 for screening breast cancer: An antibody\u2011lectin sandwich assay for detecting glycosylation of CA15\u20113 in sera","volume":"40","author":"Choi","year":"2018","journal-title":"Oncol. Rep."},{"issue":"3","key":"10.1016\/j.cca.2025.120387_b0410","doi-asserted-by":"crossref","first-page":"318","DOI":"10.5301\/JBM.5000036","article-title":"Humoral immune response against tumoral mucin 1 (MUC1) in breast cancer patients","volume":"28","author":"Isla Larrain","year":"2013","journal-title":"Int. J. Biol. Markers"},{"key":"10.1016\/j.cca.2025.120387_b0415","doi-asserted-by":"crossref","first-page":"113","DOI":"10.4137\/CMO.S29462","article-title":"Galectin-3 as a potential target to prevent cancer metastasis","volume":"9","author":"Ahmed","year":"2015","journal-title":"Clin. Med. Insights Oncol."},{"key":"10.1016\/j.cca.2025.120387_b0420","doi-asserted-by":"crossref","unstructured":"J.J. Grazier, P.W. Sylvester, Role of Galectins in Metastatic Breast Cancer, in Breast Cancer, H.N. Mayrovitz, Editor. 2022, Exon Publications Copyright: The Authors.; The authors confirm that the materials included in this chapter do not violate copyright laws. Where relevant, appropriate permissions have been obtained from the original copyright holders, and all original sources have been appropriately acknowledged or referenced.: Brisbane (AU).","DOI":"10.36255\/exon-publications-breast-cancer-galectins"},{"issue":"1","key":"10.1016\/j.cca.2025.120387_b0425","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.bbrc.2019.06.003","article-title":"Induction of Trop-2 expression through the binding of galectin-3 to MUC1","volume":"516","author":"Yamashita","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.cca.2025.120387_b0430","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/path.2993","article-title":"Silencing disease genes in the laboratory and the clinic","volume":"226","author":"Watts","year":"2012","journal-title":"J. Pathol."},{"key":"10.1016\/j.cca.2025.120387_b0435","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s11658-019-0196-3","article-title":"Editorial focus: understanding off-target effects as the key to successful RNAi therapy","volume":"24","author":"Bartoszewski","year":"2019","journal-title":"Cell. Mol. Biol. Lett."},{"issue":"1","key":"10.1016\/j.cca.2025.120387_b0440","first-page":"1","article-title":"Integrating basic science into clinical practice","volume":"4","author":"Course","year":"2010","journal-title":"Hep. Intl."},{"issue":"1","key":"10.1016\/j.cca.2025.120387_b0445","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1080\/15476286.2022.2052641","article-title":"Advances in siRNA therapeutics and synergistic effect on siRNA activity using emerging dual ribose modifications","volume":"19","author":"Gangopadhyay","year":"2022","journal-title":"RNABiol"},{"issue":"7","key":"10.1016\/j.cca.2025.120387_b0450","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13071009","article-title":"Clinical advances of siRNA-based nanotherapeutics for cancer treatment","volume":"13","author":"Hattab","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.cca.2025.120387_b0455","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jconrel.2023.07.054","article-title":"Lipid nanoparticles for siRNA delivery in cancer treatment","volume":"361","author":"El Moukhtari","year":"2023","journal-title":"J. Control. Release"},{"issue":"8","key":"10.1016\/j.cca.2025.120387_b0460","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26083456","article-title":"Recent update on siRNA therapeutics","volume":"26","author":"Ebenezer","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.cca.2025.120387_b0465","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/jcph.1553","article-title":"Pharmacokinetics of patisiran, the first approved RNA interference therapy in patients with hereditary transthyretin-mediated amyloidosis","volume":"60","author":"Zhang","year":"2020","journal-title":"J. Clin. Pharmacol."},{"issue":"7","key":"10.1016\/j.cca.2025.120387_b0470","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s40265-021-01511-3","article-title":"Givosiran: a review in acute hepatic porphyria","volume":"81","author":"Syed","year":"2021","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.cca.2025.120387_b0475","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.3390\/pharmaceutics13081239","article-title":"Development, characterization, and in vivo evaluation of a novel aptamer (Anti-MUC1\/Y) for breast cancer Therapy","volume":"13","author":"Khan","year":"2021","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.cca.2025.120387_b0480","doi-asserted-by":"crossref","first-page":"e822","DOI":"10.1002\/ctm2.822","article-title":"The role of cell-penetrating peptides in potential anti-cancer therapy","volume":"12","author":"Zhou","year":"2022","journal-title":"Clin. Transl. Med."},{"issue":"2","key":"10.1016\/j.cca.2025.120387_b0485","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s13402-024-00990-2","article-title":"Exosomes: from basic research to clinical diagnostic and therapeutic applications in cancer","volume":"48","author":"Araujo-Abad","year":"2025","journal-title":"Cell Oncol. (dordr)"},{"issue":"4","key":"10.1016\/j.cca.2025.120387_b0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e15164","article-title":"Antitumor effect of a novel humanized MUC1 antibody-drug conjugate on triple-negative breast cancer","volume":"9","author":"Li","year":"2023","journal-title":"Heliyon"},{"issue":"9","key":"10.1016\/j.cca.2025.120387_b0495","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21093258","article-title":"Novel antibodies targeting MUC1-C showed anti-metastasis and growth-inhibitory effects on human breast cancer cells","volume":"21","author":"Kim","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.cca.2025.120387_b0500","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1021\/acschembio.9b00338","article-title":"Procaspase-3 overexpression in cancer: a paradoxical observation with therapeutic potential","volume":"14","author":"Boudreau","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.cca.2025.120387_b0505","first-page":"401","article-title":"Functionalized liposomes for targeted breast cancer drug delivery","volume":"24","author":"Nel","year":"2023","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.cca.2025.120387_b0510","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.2147\/IJN.S106625","article-title":"Lipid nanoparticles for targeted siRNA delivery - going from bench to bedside","volume":"11","author":"Zatsepin","year":"2016","journal-title":"Int. J. Nanomed."},{"issue":"2","key":"10.1016\/j.cca.2025.120387_b0515","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.cca.2025.120387_b0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.nxmate.2024.100128","article-title":"Role of nanoparticles in enhancing chemotherapy efficacy for cancer treatment","volume":"2","author":"Ghazal","year":"2024","journal-title":"Next Materials"},{"issue":"1","key":"10.1016\/j.cca.2025.120387_b0525","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.molmed.2023.10.005","article-title":"Three 'E' challenges for siRNA drug development","volume":"30","author":"Guo","year":"2024","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.cca.2025.120387_b0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2022.100103","article-title":"New paradigm in combination therapy of siRNA with chemotherapeutic drugs for effective cancer therapy","volume":"3","author":"Kumar","year":"2022","journal-title":"Curr Res Pharmacol Drug Discov"},{"issue":"10","key":"10.1016\/j.cca.2025.120387_b0535","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.5858\/2004-128-1131-MGGAFM","article-title":"MUC1 gene-derived glycoprotein assays for monitoring breast cancer (CA 15-3, CA 27.29, BR): are they measuring the same antigen?","volume":"128","author":"Klee","year":"2004","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"5","key":"10.1016\/j.cca.2025.120387_b0540","first-page":"630","article-title":"Comparison of the diagnostic accuracy of CA27.29 and CA15.3 in primary breast cancer","volume":"45","author":"Gion","year":"1999","journal-title":"Clin. Chem."},{"issue":"4","key":"10.1016\/j.cca.2025.120387_b0545","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1021\/acs.jproteome.2c00475","article-title":"LC-MS\/MS-PRM quantification of IgG glycoforms Using stable isotope labeled IgG1 Fc glycopeptide standard","volume":"22","author":"Sanda","year":"2023","journal-title":"J. Proteome Res."},{"issue":"10","key":"10.1016\/j.cca.2025.120387_b0550","doi-asserted-by":"crossref","DOI":"10.1002\/pmic.202000214","article-title":"Combining label-free and label-based accurate quantifications with SWATH-MS: comparison with SRM and PRM for the evaluation of bovine muscle type effects","volume":"21","author":"Bons","year":"2021","journal-title":"Proteomics"},{"issue":"2","key":"10.1016\/j.cca.2025.120387_b0555","doi-asserted-by":"crossref","DOI":"10.1128\/jcm.01488-23","article-title":"FDA's proposed rule for the regulation of laboratory-developed tests","volume":"62","author":"Miller","year":"2024","journal-title":"J. Clin. Microbiol."},{"issue":"2","key":"10.1016\/j.cca.2025.120387_b0560","first-page":"139","article-title":"A new competitive enzyme linked immunosorbent assay (MRP83-CA15-3) for MUC1 measurement in breast cancer","volume":"27","author":"Mohammadnejad","year":"2006","journal-title":"J. ImmunoassayImmunochem"},{"key":"10.1016\/j.cca.2025.120387_b0565","doi-asserted-by":"crossref","DOI":"10.1016\/j.onano.2022.100063","article-title":"siRNA therapeutics and its challenges: recent advances in effective delivery for cancer therapy","volume":"7","author":"Paul","year":"2022","journal-title":"OpenNano"},{"issue":"Pt A","key":"10.1016\/j.cca.2025.120387_b0570","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","article-title":"PEGylation as a strategy for improving nanoparticle-based drug and gene delivery","volume":"99","author":"Suk","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.cca.2025.120387_b0575","article-title":"Advances in targeted therapy for tumor with nanocarriers: a review","volume":"31","author":"Cheng","year":"2025","journal-title":"Mater. Today Bio"},{"issue":"5","key":"10.1016\/j.cca.2025.120387_b0580","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1450","article-title":"Stimuli-responsive liposomes for drug delivery","volume":"9","author":"Lee","year":"2017","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"issue":"2","key":"10.1016\/j.cca.2025.120387_b0585","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10213","article-title":"Cytosolic delivery of nucleic acids: the case of ionizable lipid nanoparticles","volume":"6","author":"Schlich","year":"2021","journal-title":"Bioeng. Transl. Med."},{"issue":"5","key":"10.1016\/j.cca.2025.120387_b0590","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s40259-022-00549-3","article-title":"Therapeutic siRNA: state-of-the-art and future perspectives","volume":"36","author":"Friedrich","year":"2022","journal-title":"BioDrugs"},{"key":"10.1016\/j.cca.2025.120387_b0595","doi-asserted-by":"crossref","DOI":"10.1177\/11772719211047763","article-title":"Companion diagnostics: state of the art and new regulations","volume":"16","author":"Valla","year":"2021","journal-title":"Biomark. Insights"},{"key":"10.1016\/j.cca.2025.120387_b0600","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114432","article-title":"The growth of siRNA-based therapeutics: updated clinical studies","volume":"189","author":"Zhang","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.cca.2025.120387_b0605","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.trsl.2019.08.005","article-title":"siRNA therapeutics for breast cancer: recent efforts in targeting metastasis, drug resistance, and immune evasion","volume":"214","author":"Ngamcherdtrakul","year":"2019","journal-title":"Transl. Res."},{"key":"10.1016\/j.cca.2025.120387_b0610","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fonc.2018.00086","article-title":"Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations","volume":"8","author":"Seidel","year":"2018","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.cca.2025.120387_b0615","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11020176","article-title":"Releasing the immune system brakes using siRNAs enhances cancer immunotherapy","volume":"11","author":"Sioud","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cca.2025.120387_b0620","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3389\/fmolb.2020.00193","article-title":"Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance","volume":"7","author":"Yao","year":"2020","journal-title":"Front. Mol. Biosci."},{"issue":"9","key":"10.1016\/j.cca.2025.120387_b0625","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1039\/D4NA00086B","article-title":"Cutting-edge approaches for targeted drug delivery in breast cancer: beyond conventional therapies","volume":"6","author":"Chaudhari","year":"2024","journal-title":"Nanoscale Adv."},{"issue":"1","key":"10.1016\/j.cca.2025.120387_b0630","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3892\/or.2012.2097","article-title":"Combination therapy with VEGFR2 and EGFR siRNA enhances the antitumor effect of cisplatin in non-small cell lung cancer xenografts","volume":"29","author":"Chen","year":"2013","journal-title":"Oncol. Rep."},{"issue":"7","key":"10.1016\/j.cca.2025.120387_b0635","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24076121","article-title":"The small RNA landscape in NSCLC: current therapeutic applications and progresses","volume":"24","author":"Ciccone","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.cca.2025.120387_b0640","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s10198-023-01639-x","article-title":"Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy","volume":"25","author":"Michaeli","year":"2024","journal-title":"Eur. J. Health Econ."},{"issue":"10","key":"10.1016\/j.cca.2025.120387_b0645","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/nrd4101","article-title":"Considerations for the successful co-development of targeted cancer therapies and companion diagnostics","volume":"12","author":"Fridlyand","year":"2013","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898125002669?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898125002669?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T11:52:35Z","timestamp":1756036355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898125002669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":129,"alternative-id":["S0009898125002669"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2025.120387","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MUC1 as a diagnostic biomarker and siRNA-based therapeutic target in breast cancer: A clinical chemistry perspective","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2025.120387","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"120387"}}